Use of biphasic electrical cardioversion for treatment of idiopathic atrial fibrillation in two horses

Frye, Melinda A.; Selders, Corine G.; Mama, Khursheed R.; Wagner, Ann E.; Bright, Janice M.

doi:10.2460/javma.2002.220.1039

Cited by 31 publications

(22 citation statements)

References 28 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Vorhofflimmern ist weiterhin die häufigste kardiovaskuläre Ursache für einen Leistungsabfall beim Pferd (Reef 1988, Marr 1991, Mitten 1996 Eine erfolgreiche transthorakale elektrische Kardioversion beim Pferd ist bisher lediglich in einem Fall beschrieben worden (Frye et al 2002). Dabei bleibt wegen einer gleichzeitigen Gabe von Chinidinsulfat unklar, worauf der Therapieerfolg zurückzuführen war.…”

Section: Diskussionunclassified

Therapy of atrial fibrillation with class-1A and class-1C antiarrhythmic agents and ACE inhibitors

Goltz¹,

Gehlen²,

Rohn³

et al. 2009

PHK

View full text Add to dashboard Cite

(Deegen 1986, Reef 1988, Gelberg et al. 1991, Patteson 1996, DukesMcEwan 2002. Pferdeheilkunde 25 (2009) Therapy of atrial fibrillation with class-1A and class-1C antiarrhythmic agents and ACE inhibitors Atrial fibrillation can have a significant influence on the performance of horses and might represent a risk for horse and rider while riding the horse. Horses with this disease are still mainly treated with quinidine sulphate. The aim of this study was to determine whether the treatment of atrial fibrillation with quinidine sulphate could be improved, considering the sometimes unsatisfying success rate and the risk of recurrence. A first step towards this goal is to distinguish horses with a good prognosis from horses with a bad prognosis for cardioversion, for example by establishing the rate of recurrence and possible reasons for recurrence in horses that have been treated successfully. For this purpose the authors performed a retrospective study of 33 horses with atrial fibrillation that had been treated successfully with intravenously administered quinidine sulphate on an average of nine years ago. The study included a questionnaire addressed to the owners of these horses. About half of the successfully treated horses had no recurrence up to the time of the study, or until death of these horses. 24 horses were able to be treated successfully with just one quinidine sulphate infusion. Seven horses achieved cardioversion during the second and two horses during or after the third infusion. Horses which had to be treated more than once to achieve cardioversion had a significantly enlarged left atrium (p < 0,05) compared to horses which were treated successfully at the first attempt. Twelve horses were pretreated before achieving cardioversion. Seven horses received the ACE inhibitor quinaprile and the antiarrhythmic agent propafenone, five horses just propafenone. 21 horses were not pretreated. They needed significantly (p < 0,001) more attempts to achieve cardioversion than the horses that had been pretreated. However, there was no significant difference regarding the number of attempts to achieve cardioversion between horses treated only with propafenone or with both quinaprile and propafenone. So a previous treatment of horses with drugs like ACE inhibitors and/or propafenone seems to improve the prognosis for cardioversion.

show abstract

Section: Diskussionunclassified

Therapy of atrial fibrillation with class-1A and class-1C antiarrhythmic agents and ACE inhibitors

Goltz¹,

Gehlen²,

Rohn³

et al. 2009

PHK

View full text Add to dashboard Cite

show abstract

“…1 Previous studies demonstrated cTnI is highly conserved among several diverse mammalian species, 13,16 allowing veterinarians to measure cTnI in cardiac diseases in animals, including dogs, cats, and horses. 5,7,10,14,15,18,19 Results of immunoassays indicate that only protein from cardiac tissue is specifically detected by these assays in various animal species. 6,13 Reference ranges for cTnI have been determined for dogs and cats, and in case studies, cTnI was measured in normal horses to establish controls.…”

mentioning

confidence: 99%

“…In addition, the present study provides a baseline for examining cTnI polymorphisms in equine disease and performance 5,7,15,19 and for examining whether equine cTnI demonstrates different kinetic properties from cTnI of other species, which might be ascribed to the deleted 6-amino-acid region. …”

mentioning

confidence: 99%

Cloning and Sequencing of Equine Cardiac Troponin I and Confirmation of Its Usefulness as a Target Analyte for Commercial Troponin I Analyzers

Rishniw

Simpson

2005

J VET Diagn Invest

View full text Add to dashboard Cite

Abstract. The analysis of cardiac troponin I (cTnI) in the diagnosis of myocardial injury in domestic animals is gaining popularity. In this study, equine cTnI was sequenced and compared with previously characterized cTnI from other species. A 6-amino-acid N-terminal deletion unique to the horse was identified. This deletion was outside the epitope region of cTnI recognized by most commercial immunoassays and did not affect the ability of a commercial analyzer system to detect recombinant equine cTnI. No function could be ascribed to the deleted portion. These data support the use of commercial analyzers in measuring equine cTnI.

show abstract

“…Transvenous electrical cardioversion (TVEC) has been reported to be of higher efficacy than transthoracic cardioversion in humans and requires substantially lower energy levels. Successful TVEC using a conventional biphasic defibrillator has been described in horses but has not been reported in camelids . Transthoracic electrical cardioversion was attempted in the llama diagnosed with lone AF in this study (up to 200 J) but was also unsuccessful in restoring sinus rhythm.…”

Section: The Most Common Complete Blood Count and Serum Biochemical Amentioning

confidence: 73%

“…Electrical cardioversion is an established technique in addition to pharmacological cardioversion for the restoration of sinus rhythm in humans and dogs with AF . Transthoracic cardioversion has been described in horses but is considered rarely successful . Transvenous electrical cardioversion (TVEC) has been reported to be of higher efficacy than transthoracic cardioversion in humans and requires substantially lower energy levels.…”

Section: The Most Common Complete Blood Count and Serum Biochemical Amentioning

confidence: 99%

Atrial Fibrillation in Eight New World Camelids

Bozorgmanesh

Magdesian

Estell

et al. 2015

Veterinary Internal Medicne

View full text Add to dashboard Cite

BackgroundThere is limited information on the incidence of clinical signs, concurrent illness and treatment options for atrial fibrillation (AF) in New World Camelids (NWC).ObjectiveDescribe clinical signs and outcome of AF in NWC.AnimalsEight New World Camelids admitted with AF.MethodsA retrospective observational study of camelids diagnosed with AF based on characteristic findings on electrocardiogram (ECG).ResultsAll animals had an irregularly irregular heart rhythm detected on physical examination and 4 cases had obtunded mentation on admission. Three camelids were diagnosed with AF secondary to oleander intoxication, 3 animals had underlying cardiovascular disease, 1 was diagnosed with lone AF and 1 had AF diagnosed on examination for a urethral obstruction. Five of eight animals survived to discharge and nonsurvivors consisted of animals which died or were euthanized as a result of cardiovascular disease (2/8) or extra‐cardiac disease unrelated to the AF (1/8).Conclusions and Clinical ImportanceAtrial fibrillation occurs in NWC in association with cardiovascular disease, extra‐cardiac disease or as lone AF. Amiodarone and transthoracic cardioversion were attempted in one llama with lone AF, but were unsuccessful. Atrial fibrillation was recorded in 0.1% of admissions.

show abstract

Use of biphasic electrical cardioversion for treatment of idiopathic atrial fibrillation in two horses

Cited by 31 publications

References 28 publications

Therapy of atrial fibrillation with class-1A and class-1C antiarrhythmic agents and ACE inhibitors

Therapy of atrial fibrillation with class-1A and class-1C antiarrhythmic agents and ACE inhibitors

Cloning and Sequencing of Equine Cardiac Troponin I and Confirmation of Its Usefulness as a Target Analyte for Commercial Troponin I Analyzers

Atrial Fibrillation in Eight New World Camelids

Contact Info

Product

Resources

About